These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 25676389)

  • 1. Targeting human central nervous system protein kinases: An isoform selective p38αMAPK inhibitor that attenuates disease progression in Alzheimer's disease mouse models.
    Roy SM; Grum-Tokars VL; Schavocky JP; Saeed F; Staniszewski A; Teich AF; Arancio O; Bachstetter AD; Webster SJ; Van Eldik LJ; Minasov G; Anderson WF; Pelletier JC; Watterson DM
    ACS Chem Neurosci; 2015 Apr; 6(4):666-80. PubMed ID: 25676389
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel p38 alpha MAPK inhibitor suppresses brain proinflammatory cytokine up-regulation and attenuates synaptic dysfunction and behavioral deficits in an Alzheimer's disease mouse model.
    Munoz L; Ralay Ranaivo H; Roy SM; Hu W; Craft JM; McNamara LK; Chico LW; Van Eldik LJ; Watterson DM
    J Neuroinflammation; 2007 Sep; 4():21. PubMed ID: 17784957
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of Novel In Vivo Chemical Probes to Address CNS Protein Kinase Involvement in Synaptic Dysfunction.
    Watterson DM; Grum-Tokars VL; Roy SM; Schavocky JP; Bradaric BD; Bachstetter AD; Xing B; Dimayuga E; Saeed F; Zhang H; Staniszewski A; Pelletier JC; Minasov G; Anderson WF; Arancio O; Van Eldik LJ
    PLoS One; 2013; 8(6):e66226. PubMed ID: 23840427
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Retention of normal glia function by an isoform-selective protein kinase inhibitor drug candidate that modulates cytokine production and cognitive outcomes.
    Zhou Z; Bachstetter AD; Späni CB; Roy SM; Watterson DM; Van Eldik LJ
    J Neuroinflammation; 2017 Apr; 14(1):75. PubMed ID: 28381303
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An isoform-selective p38α mitogen-activated protein kinase inhibitor rescues early entorhinal cortex dysfunctions in a mouse model of Alzheimer's disease.
    Rutigliano G; Stazi M; Arancio O; Watterson DM; Origlia N
    Neurobiol Aging; 2018 Oct; 70():86-91. PubMed ID: 30007168
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Selective and Brain Penetrant p38αMAPK Inhibitor Candidate for Neurologic and Neuropsychiatric Disorders That Attenuates Neuroinflammation and Cognitive Dysfunction.
    Roy SM; Minasov G; Arancio O; Chico LW; Van Eldik LJ; Anderson WF; Pelletier JC; Watterson DM
    J Med Chem; 2019 Jun; 62(11):5298-5311. PubMed ID: 30978288
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neflamapimod: Clinical Phase 2b-Ready Oral Small Molecule Inhibitor of p38α to Reverse Synaptic Dysfunction in Early Alzheimer's Disease.
    Alam J; Blackburn K; Patrick D
    J Prev Alzheimers Dis; 2017; 4(4):273-278. PubMed ID: 29181493
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lixisenatide rescues spatial memory and synaptic plasticity from amyloid β protein-induced impairments in rats.
    Cai HY; Hölscher C; Yue XH; Zhang SX; Wang XH; Qiao F; Yang W; Qi JS
    Neuroscience; 2014 Sep; 277():6-13. PubMed ID: 24583037
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Leucettine L41, a DYRK1A-preferential DYRKs/CLKs inhibitor, prevents memory impairments and neurotoxicity induced by oligomeric Aβ25-35 peptide administration in mice.
    Naert G; Ferré V; Meunier J; Keller E; Malmström S; Givalois L; Carreaux F; Bazureau JP; Maurice T
    Eur Neuropsychopharmacol; 2015 Nov; 25(11):2170-82. PubMed ID: 26381812
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of triazolopyridazinones as potent p38α inhibitors.
    Herberich B; Jackson C; Wurz RP; Pettus LH; Sherman L; Liu Q; Henkle B; Saris CJ; Wong LM; Chmait S; Lee MR; Mohr C; Hsieh F; Tasker AS
    Bioorg Med Chem Lett; 2012 Jan; 22(2):1226-9. PubMed ID: 22196117
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selectivity, cocrystal structures, and neuroprotective properties of leucettines, a family of protein kinase inhibitors derived from the marine sponge alkaloid leucettamine B.
    Tahtouh T; Elkins JM; Filippakopoulos P; Soundararajan M; Burgy G; Durieu E; Cochet C; Schmid RS; Lo DC; Delhommel F; Oberholzer AE; Pearl LH; Carreaux F; Bazureau JP; Knapp S; Meijer L
    J Med Chem; 2012 Nov; 55(21):9312-30. PubMed ID: 22998443
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Implications for selectivity of 3,4-diarylquinolinones as p38alphaMAP kinase inhibitors.
    Peifer C; Urich R; Schattel V; Abadleh M; Röttig M; Kohlbacher O; Laufer S
    Bioorg Med Chem Lett; 2008 Feb; 18(4):1431-5. PubMed ID: 18207396
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical pharmacokinetics and metabolism of 6-(4-(2,5-difluorophenyl)oxazol-5-yl)-3-isopropyl-[1,2,4]-triazolo[4,3-a]pyridine, a novel and selective p38alpha inhibitor: identification of an active metabolite in preclinical species and human liver microsomes.
    Kalgutkar AS; Hatch HL; Kosea F; Nguyen HT; Choo EF; McClure KF; Taylor TJ; Henne KR; Kuperman AV; Dombroski MA; Letavic MA
    Biopharm Drug Dispos; 2006 Nov; 27(8):371-86. PubMed ID: 16944451
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early stage drug treatment that normalizes proinflammatory cytokine production attenuates synaptic dysfunction in a mouse model that exhibits age-dependent progression of Alzheimer's disease-related pathology.
    Bachstetter AD; Norris CM; Sompol P; Wilcock DM; Goulding D; Neltner JH; St Clair D; Watterson DM; Van Eldik LJ
    J Neurosci; 2012 Jul; 32(30):10201-10. PubMed ID: 22836255
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TrkB activation by 7, 8-dihydroxyflavone increases synapse AMPA subunits and ameliorates spatial memory deficits in a mouse model of Alzheimer's disease.
    Gao L; Tian M; Zhao HY; Xu QQ; Huang YM; Si QC; Tian Q; Wu QM; Hu XM; Sun LB; McClintock SM; Zeng Y
    J Neurochem; 2016 Feb; 136(3):620-36. PubMed ID: 26577931
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and biological activity of pyridopyridazin-6-one p38α MAP kinase inhibitors. Part 2.
    Tynebor RM; Chen MH; Natarajan SR; O'Neill EA; Thompson JE; Fitzgerald CE; O'Keefe SJ; Doherty JB
    Bioorg Med Chem Lett; 2012 Sep; 22(18):5979-83. PubMed ID: 22901390
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Curcumin Improves Amyloid β-Peptide (1-42) Induced Spatial Memory Deficits through BDNF-ERK Signaling Pathway.
    Zhang L; Fang Y; Xu Y; Lian Y; Xie N; Wu T; Zhang H; Sun L; Zhang R; Wang Z
    PLoS One; 2015; 10(6):e0131525. PubMed ID: 26114940
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Attenuation of mitochondrial and nuclear p38α signaling: a novel mechanism of estrogen neuroprotection in cerebral ischemia.
    Han D; Scott EL; Dong Y; Raz L; Wang R; Zhang Q
    Mol Cell Endocrinol; 2015 Jan; 400():21-31. PubMed ID: 25462588
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Re-engineering a neuroprotective, clinical drug as a procognitive agent with high in vivo potency and with GABAA potentiating activity for use in dementia.
    Luo J; Lee SH; VandeVrede L; Qin Z; Piyankarage S; Tavassoli E; Asghodom RT; Ben Aissa M; Fà M; Arancio O; Yue L; Pepperberg DR; Thatcher GR
    BMC Neurosci; 2015 Oct; 16():67. PubMed ID: 26480871
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The discovery of (R)-2-(sec-butylamino)-N-(2-methyl-5-(methylcarbamoyl)phenyl) thiazole-5-carboxamide (BMS-640994)-A potent and efficacious p38alpha MAP kinase inhibitor.
    Hynes J; Wu H; Pitt S; Shen DR; Zhang R; Schieven GL; Gillooly KM; Shuster DJ; Taylor TL; Yang X; McIntyre KW; McKinnon M; Zhang H; Marathe PH; Doweyko AM; Kish K; Kiefer SE; Sack JS; Newitt JA; Barrish JC; Dodd J; Leftheris K
    Bioorg Med Chem Lett; 2008 Mar; 18(6):1762-7. PubMed ID: 18313298
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.